What Is a PMCF Plan? Post-Market Surveillance Software, Requirements and EU MDR Structure

The PMCF plan defines the objectives, methods, and rationale for PMCF activities. A well-constructed plan is specific, actionable, and clearly connected to the evidence gaps and clinical questions identified in the Clinical Evaluation Report. A poorly constructed plan is generic, uncommitted, and generates no meaningful evidence.

Notified Bodies distinguish between the two consistently. A PMCF plan that commits to vague future data collection without specifying methods, timelines, or outcome parameters is one of the most common findings during conformity assessment for higher-risk devices. This article examines what a PMCF plan must contain, how it connects to the broader post-market surveillance system, and the most common mistakes that undermine its effectiveness and defensibility.

Key Takeaways

• The PMCF plan must define specific objectives, methods, timelines, and outcome parameters — vague commitments to future data collection are not sufficient
• PMCF is mandatory for Class III and implantable devices; for other device classes, a scientific justification must be provided where it is considered unnecessary
• The PMCF plan must be connected to specific clinical evidence gaps and questions identified in the CER — general statements about confirming safety and performance are not sufficient
• PMCF activities must generate real evidence; a plan that exists as a document but is not executed is a compliance gap
• PMCF findings must feed into the CER and the PSUR, and the PMCF evaluation report must be updated at least annually for Class III and implantable devices
• Literature surveillance is a recognised PMCF method and must be structured, documented, and conducted continuously
• The PMCF plan and PMS plan are distinct documents with different purposes; understanding this distinction is essential for regulatory planning

Table of Contents

1. Direct Answer: What Is a PMCF Plan?
2. Why It Matters: PMCF Obligations Under EU MDR
3. How It Works: PMCF Plan Structure and Required Elements
   • Required Elements Under Annex XIV Part B
   • PMCF Objectives Must Be Specific
   • PMCF Methods
   • Literature Surveillance as a PMCF Method
   • Post-Market Surveillance Software and PMCF Execution
   • Timelines and Frequency
   • Connection to the CER
   • PMCF Plan vs PMS Plan
4. Common Mistakes: PMCF Plan Problems That Affect Regulatory Review
5. Best Practices: How to Build a Defensible PMCF Plan
6. Comparison Table
7. Checklist
8. Definitions
9. Expert Perspective
10. FAQ
11. References
12. Related Resources
13. Call to Action

Direct Answer: What Is a PMCF Plan?

A Post-Market Clinical Follow-Up plan is the document that defines the objectives, methods, and rationale for PMCF activities. Under Annex XIV Part B of EU MDR, the PMCF plan must address a defined set of elements, including the general methods and procedures to be applied, the specific objectives to be addressed, an evaluation of the clinical data relating to equivalent or similar devices, specific methods such as registries, post-market clinical investigations, epidemiological studies, literature reviews, or user surveys, rationale and references to relevant parts of the CER, and reference to any relevant common specifications or harmonised standards.

The PMCF plan is not a statement of intent. It is a structured document that defines what will be done, how it will be done, when it will be done, and what outcomes are expected. Notified Bodies assess the plan against this standard. A plan that does not meet it generates findings.

Why It Matters: PMCF Obligations Under EU MDR

Under EU MDR, clinical evaluation is a continuous lifecycle obligation. PMCF is the primary mechanism through which manufacturers generate new clinical data after market entry to maintain and update that evaluation. Its findings feed directly into the CER, the Periodic Safety Update Report, and the risk management file.

For Class III and implantable devices, PMCF is mandatory under Annex XIV Part B. For other device classes, manufacturers must either conduct PMCF activities or provide a clear scientific justification for why they are not necessary. This justification must be well-founded and documented in the PMCF plan. Notified Bodies scrutinise the reasoning carefully, particularly for higher-risk devices.

The consequences of inadequate PMCF planning are significant. A PMCF plan that is generic, uncommitted, or disconnected from the clinical evidence gaps in the CER will generate findings during conformity assessment. A PMCF plan that exists as a document but has not resulted in actual data collection is a compliance gap that becomes visible during Notified Body surveillance audits. And a device with no meaningful PMCF evidence accumulating over time will face increasing difficulty justifying its benefit-risk profile as post-market experience grows.

How It Works: PMCF Plan Structure and Required Elements

Required Elements Under Annex XIV Part B

Annex XIV Part B of EU MDR defines the elements that must be addressed in a PMCF plan. These are not optional. The plan must cover all of the following:

The general methods and procedures to be applied in PMCF, including the methods for collecting and processing data, the approach to quality assurance, and how findings will be documented and reported.

The specific objectives to be addressed by the PMCF activities. These must be connected to specific clinical questions or evidence gaps identified in the CER. General statements about confirming safety and performance are not specific objectives.

An evaluation of the clinical data relating to equivalent or similar devices where available. Where clinical data from comparable devices provides relevant context for interpreting PMCF findings, this should be addressed in the plan.

Specific methods such as registries, post-market clinical investigations, epidemiological studies, literature surveillance, and user surveys. The plan must define which methods will be used, the rationale for their selection, and how they will address the specific PMCF objectives.

Rationale for the appropriateness of the methods chosen, with references to relevant parts of the CER that demonstrate the connection between the plan and the clinical evidence assessment.

Reference to any relevant common specifications or harmonised standards applicable to the PMCF activities.

PMCF Objectives Must Be Specific

One of the most common PMCF plan deficiencies is the absence of specific, measurable objectives. A PMCF objective such as “to confirm the safety and performance of the device in clinical use” is not a specific objective. It does not identify which aspects of safety or performance need to be confirmed, in which patient population, over what time period, using what outcome measures, or what evidence threshold would constitute confirmation.

A well-constructed PMCF objective addresses a specific clinical question identified in the CER. For example: to evaluate the long-term implant survival rate of the device at five years in patients with a defined clinical indication, using a defined registry with a defined sample size and defined follow-up protocol. That is a specific, measurable, and defensible objective.

PMCF Methods

Annex XIV Part B identifies specific PMCF methods that may be used. These include:

Post-market clinical investigations: Structured clinical studies conducted on the marketed device. These provide the highest level of clinical evidence for PMCF purposes and are particularly appropriate for addressing specific safety or performance questions that cannot be answered through other means.

Registries: Systematic data collection from patients treated with the device across multiple clinical sites. Registries provide real-world clinical data at scale and are particularly valuable for long-term follow-up and rare event identification.

Epidemiological studies: Studies designed to assess the frequency and distribution of device-related outcomes in defined populations.

Literature surveillance: Systematic and documented review of published clinical and scientific literature relating to the device, its analytes, comparable technologies, and related clinical areas. Literature surveillance is a recognised and commonly used PMCF method, particularly for established device technologies with a substantial published evidence base.

User surveys and registry data: Collection of structured feedback from healthcare professionals or patients regarding device performance, usability, and clinical outcomes.

The choice of PMCF methods must be justified in the plan. The justification should explain why the selected methods are appropriate for addressing the specific PMCF objectives, proportionate to the device’s risk and the nature of the evidence gaps, and consistent with the CER methodology. MDCG 2020-7 provides additional guidance on PMCF methods and their application.

Literature Surveillance as a PMCF Method

Literature surveillance is explicitly recognised as a PMCF method under Annex XIV Part B and is one of the most widely used approaches for ongoing clinical evidence generation. To function effectively as a PMCF method, literature surveillance must meet the same standards of methodology and documentation that apply to other systematic literature reviews.

This means predefined search strategies with documented databases, search terms, and inclusion and exclusion criteria; structured screening and selection processes with documented exclusion rationale; critical appraisal of included publications; PRISMA-aligned documentation; and a continuous monitoring process that identifies new publications as they are published rather than conducting searches at infrequent intervals.

A literature search that is conducted annually without a structured methodology and documented process does not meet the standard expected for a PMCF method under EU MDR. For a full breakdown of the structured literature review methodology expected under EU MDR see our article on how to conduct an EU MDR literature review.

Post-Market Surveillance Software and PMCF Execution

One of the most consistent gaps between a well-written PMCF plan and a well-executed one is the absence of systems capable of supporting continuous data collection, literature surveillance, and documentation without significant manual overhead. Post-market surveillance software that integrates literature surveillance, PMCF data management, and CER evidence integration directly addresses this gap.

CiteMed’s Evidence Cloud is purpose-built post-market surveillance software for medical device manufacturers. Its Living Reviews functionality monitors PubMed, Embase, and other databases continuously against defined search criteria, automatically notifying teams when new matching publications are available and importing them directly into the existing review. This eliminates the manual re-run cycle that causes literature surveillance to fall behind between PMCF update cycles.

The platform also supports structured clinical data extraction, PRISMA-aligned documentation, and a complete audit trail across the full evidence lifecycle, ensuring that PMCF literature surveillance meets the methodological standard expected under EU MDR rather than functioning as an undocumented search exercise.

Timelines and Frequency

The PMCF plan must define clear timelines for each activity. This includes when activities will begin, how long they will run, at what intervals interim findings will be assessed, and when the PMCF evaluation report will be updated. For Class III and implantable devices, the PMCF evaluation report must be updated at least annually and its findings must feed into the CER update.

Timelines must be realistic and consistent with the chosen methods. A PMCF plan that commits to a five-year registry study as its primary evidence source must also address how evidence needs will be met in the interim period before registry data matures.

Connection to the CER

The PMCF plan must reference relevant parts of the CER to demonstrate the connection between PMCF objectives and the clinical evidence assessment. This connection is essential for establishing that PMCF activities are designed to address real evidence gaps rather than to generate data for its own sake.

The CER should identify the specific clinical questions, evidence gaps, or uncertainties that PMCF is designed to address. The PMCF plan should then define activities that are specifically designed to answer those questions, with outcome measures and timelines that reflect what confirmation would look like.

PMCF Plan vs PMS Plan

The PMCF plan and the PMS plan are distinct documents with different purposes.

The PMCF plan feeds into and is informed by the PMS system, but it is not the same document and should not be combined with the PMS plan. Notified Bodies assess each separately.

Common Mistakes: PMCF Plan Problems That Affect Regulatory Review

Vague objectives that do not address specific clinical questions

The most common PMCF plan deficiency is the absence of specific, measurable objectives connected to identified evidence gaps. A PMCF plan that states the objective is to “confirm ongoing safety and performance” without identifying which aspects of safety or performance need confirmation, in which population, using which outcome measures, does not meet the standard expected under Annex XIV Part B.

Activities committed but not executed

A PMCF plan that commits to specific activities but does not result in actual data collection is a compliance gap that Notified Bodies identify during surveillance audits. The plan must be operationalised. Activities must be initiated, data must be collected, and findings must be documented in the PMCF evaluation report.

Literature surveillance conducted without a structured methodology

Where literature surveillance is listed as a PMCF method but is conducted without predefined search strategies, documented inclusion and exclusion criteria, structured screening, and PRISMA-aligned reporting, it does not meet the standard expected for a systematic review method. For more detail on the methodology required see our article on common literature review challenges.

Disconnection between the PMCF plan and the CER

Where the PMCF plan does not reference or connect to the CER, it is not possible to demonstrate that PMCF activities are designed to address real evidence gaps. The plan and the CER must be read together to show that PMCF is a purposeful continuation of the clinical evaluation, not a generic compliance exercise.

PMCF evaluation report not updated annually

For Class III and implantable devices, the PMCF evaluation report must be updated at least annually with the findings of PMCF activities. A report that has not been updated within the required timeframe is a compliance gap that affects the CER update and the PSUR benefit-risk assessment. For a full breakdown of how documentation gaps affect regulatory submissions see our article on reasons Clinical Evaluation Reports are rejected.

Confusing the PMCF plan with the PMS plan

Combining the PMCF plan and PMS plan into a single document, or treating them as interchangeable, creates confusion about the distinct obligations each is designed to address. Notified Bodies assess each document separately.

Best Practices: How to Build a Defensible PMCF Plan

A defensible PMCF plan is specific, connected, and operational. It addresses real clinical questions, commits to achievable methods, defines measurable outcomes, and results in evidence being generated.

Start with the CER evidence gaps

The PMCF plan should begin with the specific clinical questions, evidence gaps, or uncertainties identified in the CER. Each PMCF objective should be traceable to a specific gap in the clinical evidence assessment. This connection must be explicitly referenced in the plan.

Define specific, measurable objectives

Each objective must identify what is being confirmed, in which population, using which outcome measures, over what time period, and what threshold of evidence would constitute confirmation. If the objective cannot be described in these terms, it is not specific enough to be defensible.

Select methods that are proportionate and appropriate

The methods selected must be capable of addressing the specific PMCF objectives. Literature surveillance is appropriate for evidence gaps that can be addressed through published data. Post-market clinical investigations or registries are appropriate for questions that require new data generation. The justification for each method must be documented in the plan.

Make literature surveillance genuinely systematic

Where literature surveillance is a PMCF method, it must be conducted with the same rigour as a systematic review. Predefined search strategies, documented inclusion and exclusion criteria, structured screening, and PRISMA-aligned reporting are required. CiteMed’s Living Reviews functionality supports continuous literature surveillance by monitoring defined databases and automatically identifying new matching publications, ensuring that the PMCF literature evidence base remains current without manual re-runs.

Define realistic timelines

Each activity must have a defined start date, duration, interim review points, and completion date. Timelines must be consistent with the method. If the primary evidence source requires several years to mature, the plan must address how evidence needs will be met in the interim.

Ensure findings feed into the CER and PSUR

The PMCF evaluation report must be updated at least annually for Class III and implantable devices, and its findings must be reflected in the CER update and the PSUR benefit-risk evaluation. Build this connection into the PMCF plan from the outset so that the flow of evidence from PMCF activities to regulatory documentation is documented and systematic.

Comparison Table: PMCF Plan vs PMCF Evaluation Report

Checklist: PMCF Plan Readiness Under EU MDR

Objectives:

• Specific clinical questions or evidence gaps addressed by the PMCF plan are identified
• Each objective is specific, measurable, and connected to a defined evidence gap in the CER
• Outcome measures and evidence thresholds are defined for each objective
• References to relevant parts of the CER are included

Methods:

• Specific PMCF methods are defined for each objective
• The rationale for each method is documented and justified
• Literature surveillance is conducted with a predefined methodology including search strategies, inclusion and exclusion criteria, and PRISMA-aligned reporting
• Any relevant common specifications or harmonised standards are referenced

Timelines:

• Start dates, durations, and completion dates are defined for each activity
• Interim review points are established
• Timelines are consistent with the methods selected and realistic given available resources

Execution:

• PMCF activities are being executed and generating data
• Literature surveillance is continuous rather than conducted at infrequent intervals
• PMCF evaluation report is updated at least annually for Class III and implantable devices
• Post-market surveillance software is in place to support continuous literature surveillance, structured data collection, and audit-ready PMCF documentation

Integration:

• PMCF findings are reflected in CER updates
• PMCF evaluation report findings feed into the PSUR benefit-risk assessment
• PMCF plan is consistent with and distinct from the PMS plan
• Where PMCF is considered unnecessary for non-mandatory device classes, a documented scientific justification is provided

Definitions

Post-Market Clinical Follow-Up (PMCF)
The structured process through which manufacturers proactively collect clinical data on their device after market entry. Required under Annex XIV Part B of EU MDR. Mandatory for Class III and implantable devices; must be justified where considered unnecessary for other classes.

PMCF Plan
The document that defines the objectives, methods, timelines, and rationale for PMCF activities. Required under Annex XIV Part B. Must address specific elements defined in the regulation and be connected to the clinical evidence assessment in the CER.

PMCF Evaluation Report
The document that presents the findings and conclusions of PMCF activities. Must be updated at least annually for Class III and implantable devices. Findings must feed into the CER update and the PSUR benefit-risk assessment.

Post-Market Surveillance Plan
The document that defines the post-market surveillance system, including all data sources, collection methods, analysis processes, and escalation thresholds. Distinct from the PMCF plan, which specifically addresses proactive clinical data collection.

Literature surveillance
The systematic and continuous monitoring of published scientific and clinical literature for new evidence relating to the device, comparable technologies, and related clinical areas. A recognised PMCF method under Annex XIV Part B that must be conducted with a structured methodology and documented process.

MDCG 2020-7
A guidance document from the Medical Device Coordination Group providing guidance on PMCF under EU MDR, including the methods that may be used and how the plan and evaluation report should be structured.

Clinical evidence gap
A specific area where the available clinical evidence does not sufficiently demonstrate the device’s safety, clinical performance, or clinical benefit for its intended purpose or in a specific patient population. PMCF objectives must address specific evidence gaps identified in the CER.

Post-market surveillance software
Platforms that support the ongoing collection, analysis, and reporting of post-market data including literature surveillance, complaint trending, vigilance reporting, and PMCF monitoring. Under EU MDR, post-market surveillance must be active and continuous rather than periodic, making dedicated software support essential for manufacturers of higher-risk devices.

Expert Perspective

The PMCF plans that generate findings during Notified Body review are almost always the ones that were written to satisfy a documentation requirement rather than to answer a clinical question. They commit to activities without defining what confirmation would look like. They reference literature surveillance without specifying a search methodology. They connect to the CER in general terms rather than referencing specific evidence gaps. And they do not result in any evidence being generated because they were never intended to. A PMCF plan that is not designed to generate evidence is not a plan. It is a document that describes the absence of one.

Frequently Asked Questions

What is a PMCF plan and what must it contain?

A PMCF plan defines the objectives, methods, timelines, and rationale for Post-Market Clinical Follow-Up activities. Under Annex XIV Part B of EU MDR, it must address the general methods and procedures to be applied, specific objectives connected to clinical evidence gaps in the CER, an evaluation of data from equivalent or similar devices, specific PMCF methods with justification, references to relevant parts of the CER, and references to applicable common specifications or harmonised standards. MDCG 2020-7 provides additional guidance on PMCF plan requirements.

Is PMCF mandatory under EU MDR?

PMCF is mandatory for Class III and implantable devices under Annex XIV Part B. For other device classes, manufacturers must either conduct PMCF activities or provide a documented scientific justification for why PMCF is considered unnecessary. This justification must be well-founded and is scrutinised carefully by Notified Bodies for higher-risk devices.

What PMCF methods are accepted under EU MDR?

Annex XIV Part B identifies several accepted PMCF methods including post-market clinical investigations, patient registries, epidemiological studies, systematic literature surveillance, and user surveys. The choice of methods must be justified and appropriate for addressing the specific PMCF objectives. MDCG 2020-7 provides further guidance on the application of each method.

How does literature surveillance function as a PMCF method?

Literature surveillance is a recognised PMCF method that involves the systematic and continuous monitoring of published clinical and scientific literature. To function effectively as a PMCF method, it must be conducted with a structured methodology including predefined search strategies, documented inclusion and exclusion criteria, structured screening with documented exclusion rationale, and PRISMA-aligned reporting. A literature search conducted annually without a structured methodology does not meet the standard expected for this method under EU MDR. CiteMed’s Living Reviews functionality supports continuous literature surveillance by monitoring defined databases and automatically identifying new matching publications without manual re-runs.

How often must the PMCF evaluation report be updated?

For Class III and implantable devices, the PMCF evaluation report must be updated at least annually with the findings of PMCF activities. Its findings must be reflected in the CER update and the PSUR benefit-risk assessment. A PMCF evaluation report that has not been updated within the required timeframe is a compliance gap that affects the alignment of the technical file.

What is the difference between a PMCF plan and a PMS plan?

The PMCF plan defines the specific proactive clinical data collection activities that will be conducted after market entry to address identified clinical evidence gaps. The PMS plan defines the broader post-market surveillance system covering all data sources including complaints, vigilance, literature, and PMCF. The two documents have different regulatory bases, different purposes, and are assessed separately by Notified Bodies. They must not be combined or treated as interchangeable.

What are the most common PMCF plan mistakes?

The most common mistakes include vague objectives that do not address specific clinical evidence gaps, activities committed in the plan but not executed, literature surveillance conducted without a structured methodology, disconnection between the PMCF plan and the CER, failure to update the PMCF evaluation report at least annually for Class III and implantable devices, and confusing the PMCF plan with the PMS plan. For a full breakdown of how documentation gaps affect regulatory submissions see our article on reasons Clinical Evaluation Reports are rejected.

What post-market surveillance software supports PMCF execution under EU MDR?

Post-market surveillance software that supports PMCF execution should provide continuous literature surveillance without manual re-runs, structured clinical data extraction, PRISMA-aligned documentation, and a complete audit trail connecting PMCF findings to CER updates and the PSUR benefit-risk assessment. CiteMed’s Evidence Cloud is designed specifically for this purpose, combining post-market surveillance software capabilities with the clinical evidence management tools needed to execute and document PMCF activities that meet EU MDR expectations. Book a demo to see Evidence Cloud in action.

References

• Regulation (EU) 2017/745 on medical devices (EU MDR) — particularly Article 61 and Annex XIV
• MDCG 2020-7: Guidance on PMCF under EU MDR
• MEDDEV 2.7/1 Revision 4: Clinical Evaluation Guide
• PRISMA 2020 Statement

Related Resources

• PMCF Surveys Solution — Structured PMCF activities supporting ongoing clinical evidence generation
• Post-Market Surveillance Under EU MDR — Building a proactive PMS system aligned with EU MDR expectations
• CER Checklist for EU MDR — A practical framework for pre-submission review of Clinical Evaluation Reports
• Why Clinical Evaluation Reports Are Rejected — Common reasons CERs fail Notified Body review
• EU MDR Literature Review Services — Structured literature surveillance supporting PMCF and CER maintenance
• PRISMA and EU MDR Literature Review — Structured literature review methodology supporting PMCF literature surveillance
• PSUR vs PMSR Under EU MDR — Understanding post-market surveillance reporting requirements
• EU MDR Consulting Services — Expert support for PMCF planning and post-market surveillance strategy

Call to Action

If you are developing a PMCF plan, reviewing an existing plan before Notified Body assessment, or building a more structured approach to post-market clinical follow-up and literature surveillance under EU MDR, Citemeds can help. Get in touch to discuss your requirements.